Lloyd Payne is Executive Vice President of Anti-infectives at Evotec, a multinational preclinical drug discovery organisation, and site head of the Manchester (UK) site where much of the company’s anti-infective discovery and translational biology is performed. As part of his role, Lloyd Payne leads global anti-infective operations and sits on the executive committee that is responsible for Evotec’s global CRO business. Prior to Evotec, Lloyd Payne was the founding CEO of Euprotec Ltd, a leading biology CRO dedicated to the delivery of specialist biology services to companies involved in the discovery and development of new antimicrobial agents. Lloyd Payne led the company from foundation in 2008 through significant growth, collaborating with numerous companies worldwide, and to a successful sale and integration into Evotec.
Prior to co-founding Euprotec, Lloyd Payne was a medicinal chemist and worked on a range of programs in the oncology, inflammation, and infectious disease therapeutic areas. He was Chief Scientific Officer of a UK-based biopharmaceutical company focused on the development of novel classes of drug for the treatment of life-threatening fungal infections. Earlier in his career, Lloyd Payne was a senior medicinal chemist and Group Leader at Millennium Pharmaceuticals (now Takeda), based in the UK and the US.
Lloyd Payne has a strong passion for building innovative drug discovery partnerships and collaborating with companies to develop new drugs to treat serious infections. Lloyd Payne holds a PhD in synthetic organic chemistry, has published research in peer-reviewed journals, presented at conferences, and is a co-inventor on multiple patents related to drug discovery technologies as well as novel agents for the treatment of cancer, inflammation, and infection.